Biblio
BEAM Vs BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN'S LYMPHOMA. Biol Blood Marrow Transplant. 2019.
Cell Therapy Informatics: Updates on the integration of HCT/IEC functionalities into an electronic medical record system in the US to promote efficiency, patient safety, research, and data interoperability. Transplant Cell Ther. 2023.
Comparison of Two Doses of Antithymocyte Globulin in Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Biol Blood Marrow Transplant. 2019.
Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant. 2019.
Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.
Lower Dose of Antithymocyte Globulin (ATG) does not increase Graft-vs-Host Disease (GVHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT). Leuk Lymphoma. 2014:1-20.
Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2022.
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629-637.
A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma. Biol Blood Marrow Transplant. 2020.
Secondary impact of the COVID-19 pandemic on patients and the cell therapy healthcare ecosystem. Transplant Cell Ther. 2022.
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560-572.
Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2015:1-5.